Grip Molecular takes a different approach to diagnostics by replacing chemical assays with graphene-enabled and dielectrophoresis-enhanced, solid-state electronics.
Designed for point-of-care diagnostics, the technology may be used for multiple diseases in a single test, according to the company. Its biosensor wirelessly transmits the data to a standard cell phone or another mobile device where it is displayed. No electric cables or a separate reader are required.
Grip’s first product will address a combination of upper respiratory infections, such as COVID-19, influenza, and RSV, according to the company’s website.